Clinical Trial Update: Chronic Evaluation of Respicardia Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Respicardia therapy for sleep-disordered breathing including Cheyne-Stokes respiration has completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Sleep Apnea
• Cheyne-stokes Respiration
• Sleep Apnea
• Sleep-disordered Breathing

Drugs mentioned

• Respicardia Therapy

Snippet

Sponsor: Respicardia, Inc. | Conditions: Sleep Disordered Breathing, Cheyne Stokes Respiration | Phase 2 | Status: COMPLETED | Results posted: 2015-08-31